Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 17/20 | 0.67 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126828 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2730259 | 0.80 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL5044839 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL7077754 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL1024261 | 0.80 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6878562 | 0.79 | CYP11B1 (0.70) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.78 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2730687 | 0.76 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2729398 | 0.75 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2731776 | 0.75 | CYP11B1 (1.00) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | disclosed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | disclosed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | disclosed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | disclosed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | CYP11B1 1644/4885CYP11B2 1684/4885CYP19A1 2903/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | CYP11B1 1644/4885CYP11B2 1684/4885CYP19A1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.